PZRXQ (PhaseRx) Total Liabilities: $6.34 Mil (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PhaseRx Total Liabilities?

PhaseRx PZRXQ -99.00% Total Liabilities is $6.34 Mil as of Sep. 2017.

PhaseRx's Total Liabilities for the quarter that ended in Sep. 2017 was $6.34 Mil.

PhaseRx's quarterly Total Liabilities declined from Mar. 2017 ($7.38 Mil) to Jun. 2017 ($6.98 Mil) and declined from Jun. 2017 ($6.98 Mil) to Sep. 2017 ($6.34 Mil).

PhaseRx's annual Total Liabilities increased from Dec. 2014 ($44.20 Mil) to Dec. 2015 ($52.80 Mil) but then declined from Dec. 2015 ($52.80 Mil) to Dec. 2016 ($7.15 Mil).

PhaseRx Total Liabilities Historical Data

* Premium members only.

The historical data trend for PhaseRx's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhaseRx Total Liabilities Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
Total Liabilities
44.20 52.80 7.15

PhaseRx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.87 7.15 7.38 6.98 6.34

PhaseRx Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

PhaseRx's Total Liabilities for the fiscal year that ended in Dec. 2016 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.024+(5.127+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=7.15

Total Liabilities=Total Assets (A: Dec. 2016 )-Total Equity (A: Dec. 2016 )
=16.448-9.297
=7.15

PhaseRx's Total Liabilities for the quarter that ended in Sep. 2017 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.728+(3.611+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6.34

Total Liabilities=Total Assets (Q: Sep. 2017 )-Total Equity (Q: Sep. 2017 )
=6.038--0.301
=6.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $6.34 Mil mean?
PhaseRx (PZRXQ) has a Total Liabilities of $6.34 Mil as of Sep. 2017. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PhaseRx and its competitors.
Is PhaseRx's Total Liabilities too high?
PhaseRx's current Total Liabilities is $6.34 Mil.
How does PhaseRx's Total Liabilities compare to NSPX and HSTC?
PhaseRx's Total Liabilities of $6.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PhaseRx and its competitors. PhaseRx's current Total Liabilities is $6.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhaseRx stock overvalued right now?
PhaseRx (PZRXQ) has a current Total Liabilities of $6.34 Mil. The current Total Liabilities is $6.34 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For PhaseRx (PZRXQ), the current Total Liabilities is $6.34 Mil as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PhaseRx Business Description

Address 410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.